ADONIS Medical Group will continue developing exosome therapy based on its own biotechnology laboratory developments at its branch in Obukhov.
According to ADONIS’ press release, this area of the medical group includes its own biotechnology laboratory, cryobank, and a line of cell-free Exoprove preparations, the production of which has been established in the biotechnology laboratory at the Obukhov branch.
“Our own production allows us to guarantee the stable quality and biosafety of our products. Each batch undergoes multi-level control and has a product passport. We are developing cell-free treatment approaches for various areas of medicine, from orthopedics to gynecology,” the biotechnology laboratory notes.
Exosomes are the smallest extracellular nanoparticles that transmit regulatory signals between cells, activate physiological and reparative processes in the body, and, in particular, promote tissue regeneration and reduce systemic and local inflammation. They help cells restore their functions and maintain the body’s homeostasis. Thanks to these properties, exosome therapy is used for chronic, autoimmune, and neurological diseases, as well as in cosmetology and trichology.
The EXOPROVE line includes several cell-free preparations with clearly defined areas of application, in particular for dermatology and cosmetology, hair restoration, systemic anti-inflammatory therapy, gynecological practice and ART, and regenerative orthopedics.
All developments are based on the ADONIS medical group’s cord blood bank and other human tissues and cells, which ensures complete quality control of cell-free products at all stages — from testing donor material to the release and proper storage of the finished product.
ADONIS is a multidisciplinary medical center for adults and children, founded in 1997. Currently, the medical group of companies includes seven modern clinics in Kyiv and the region, more than 80 areas of medicine, its own laboratories, operating centers, hospitals, and departments of specialized specialists.
